Companies

Novo Nordisk Launches Bidding War With Pfizer for Metsera Acquisition

Novo Nordisk’s unsolicited bid for Metsera came a month after Pfizer’s deal with the firm. Pfizer said it will ‘pursue all legal avenues’ to protect its rights.
Google LogoMark Us Preferred on Google
Novo Nordisk Launches Bidding War With Pfizer for Metsera Acquisition
The logo of Danish pharmaceutical company Novo Nordisk at their headquarters in Bagsvaerd, Denmark, on Feb. 1, 2017. Liselotte Sabroe/Scanpix Denmark/AFP via Getty Images
Mary Prenon
Mary Prenon
Freelance Reporter
|Updated:
0:00

Novo Nordisk, the Denmark-based Ozempic creator, has launched a bidding war with Pfizer Inc. to acquire New York-based Metsera Inc.

Founded in 2022, Metsera is a clinical-stage biopharmaceutical firm specializing in treatments for obesity and metabolic diseases.

Google LogoMark Us Preferred on Google
Mary Prenon
Mary Prenon
Freelance Reporter
Mary T. Prenon covers real estate and business. She has been a writer and reporter for over 25 years with various print and broadcast media in New York.